119 related articles for article (PubMed ID: 19738391)
21. The voltage-gated sodium channel gene SCN2A and idiopathic generalized epilepsy.
Haug K; Hallmann K; Rebstock J; Dullinger J; Muth S; Haverkamp F; Pfeiffer H; Rau B; Elger CE; Propping P; Heils A
Epilepsy Res; 2001 Dec; 47(3):243-6. PubMed ID: 11738931
[TBL] [Abstract][Full Text] [Related]
22. Oxaliplatin-associated neuropathy: a review.
Cersosimo RJ
Ann Pharmacother; 2005 Jan; 39(1):128-35. PubMed ID: 15590869
[TBL] [Abstract][Full Text] [Related]
23. [Evidence from basic studies on mechanisms and treatment drugs for oxaliplatin-induced peripheral neuropathy].
Egashira N; Kawashiri T; Oishi R
Nihon Yakurigaku Zasshi; 2013 Feb; 141(2):66-70. PubMed ID: 23391544
[No Abstract] [Full Text] [Related]
24. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression.
Kwan P; Poon WS; Ng HK; Kang DE; Wong V; Ng PW; Lui CH; Sin NC; Wong KS; Baum L
Pharmacogenet Genomics; 2008 Nov; 18(11):989-98. PubMed ID: 18784617
[TBL] [Abstract][Full Text] [Related]
25. A possible link of oxaliplatin-induced neuropathy with potassium channel deficit.
Dimitrov AG; Dimitrova NA
Muscle Nerve; 2012 Mar; 45(3):403-11. PubMed ID: 22334175
[TBL] [Abstract][Full Text] [Related]
26. Missense mutation of the sodium channel gene SCN2A causes Dravet syndrome.
Shi X; Yasumoto S; Nakagawa E; Fukasawa T; Uchiya S; Hirose S
Brain Dev; 2009 Nov; 31(10):758-62. PubMed ID: 19783390
[TBL] [Abstract][Full Text] [Related]
27. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.
Grolleau F; Gamelin L; Boisdron-Celle M; Lapied B; Pelhate M; Gamelin E
J Neurophysiol; 2001 May; 85(5):2293-7. PubMed ID: 11353042
[TBL] [Abstract][Full Text] [Related]
28. [Clinical and electrophysiological studies of oxaliplatin-induced peripheral neuropathy].
Liu LZ; Wu JY; Wu ZY; Chen ZH; Ling L; Sun B; Li YF; Huang XS
Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(13):1021-5. PubMed ID: 27055794
[TBL] [Abstract][Full Text] [Related]
29. The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?
Park SB; Lin CS; Krishnan AV; Kiernan MC
Cancer Chemother Pharmacol; 2011 May; 67(5):1189-90; author reply 1191-2. PubMed ID: 21327679
[No Abstract] [Full Text] [Related]
30. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
Amara S
Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
[TBL] [Abstract][Full Text] [Related]
31. Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study.
Argyriou AA; Briani C; Cavaletti G; Bruna J; Alberti P; Velasco R; Lonardi S; Cortinovis D; Cazzaniga M; Campagnolo M; Santos C; Kalofonos HP
Eur J Neurol; 2013 May; 20(5):788-94. PubMed ID: 23252594
[TBL] [Abstract][Full Text] [Related]
32. Xaliproden lessens oxaliplatin-mediated neuropathy.
Susman E
Lancet Oncol; 2006 Apr; 7(4):288. PubMed ID: 16598880
[No Abstract] [Full Text] [Related]
33. Oxaliplatin induced-neuropathy in digestive tumors.
Sereno M; Gutiérrez-Gutiérrez G; Gómez-Raposo C; López-Gómez M; Merino-Salvador M; Tébar FZ; Rodriguez-Antona C; Casado E
Crit Rev Oncol Hematol; 2014 Jan; 89(1):166-78. PubMed ID: 24029604
[TBL] [Abstract][Full Text] [Related]
34. The pain with platinum: oxaliplatin and neuropathy.
Kiernan MC
Eur J Cancer; 2007 Dec; 43(18):2631-3. PubMed ID: 17977714
[No Abstract] [Full Text] [Related]
35. Calcium and magnesium for oxaliplatin-induced neuropathy.
Stansfield L
Am J Health Syst Pharm; 2014 Jun; 71(12):987-8. PubMed ID: 24865753
[No Abstract] [Full Text] [Related]
36. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
[TBL] [Abstract][Full Text] [Related]
37. [Basic evidence for efficacy of Goshajinkigan on oxaliplatin-induced neuropathy].
Ushio S; Kawashiri T; Egashira N
Nihon Yakurigaku Zasshi; 2014 Mar; 143(3):126-30. PubMed ID: 24614635
[No Abstract] [Full Text] [Related]
38. [Peripheral neuropathy induced by anticancer drugs].
Oishi R; Egashira N
Fukuoka Igaku Zasshi; 2013 May; 104(5):71-80. PubMed ID: 23885391
[No Abstract] [Full Text] [Related]
39. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy.
Penz M; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Scheithauer W
Ann Oncol; 2001 Mar; 12(3):421-2. PubMed ID: 11332158
[No Abstract] [Full Text] [Related]
40. The case of the tingling toes.
Eisenberg S
ONS Connect; 2011 Sep; 26(9):17. PubMed ID: 21954796
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
